Mesoblast insists Teva partnership is strong
19 June, 2012 by Dylan Bushell-EmblingMesoblast (ASX:MSB) has defended the strength of its relationship with key partner Teva Pharmaceutical Industries, calling rumors that Teva is not committed to the tie-up “unfounded.”
Immuron raises $442k in undersubscribed SPP
19 June, 2012 by Dylan Bushell-EmblingImmuron (ASX:IMC) has raised just over $442,000 in a share purchase plan (SPP), less than half of the $1 million target.
R&D Tax Incentive attracts MS clinical trial
19 June, 2012 by AusBiotechNew Zealand-based Innate Immunotherapeutics has announced the company will proceed with plans to conduct a Phase IIB clinical trial in Australia, after positive interim data from the company’s Phase I/II clinical trial of MIS416 in patients with chronic progressive multiple sclerosis (MS).
Bionomics ends MS collaboration with Merck Serono
15 June, 2012 by Dylan Bushell-EmblingBionomics (ASX:BNO) will cease collaborating with Merck Serono to develop autoimmune disorder treatments, and seek alternate partners for its Kv1.3 program.
What the Raising the Bar research exemption means for biotech
15 June, 2012 by Tim DeanThe research exemption in the new Raising the Bar bill allows experimentation on patented processes, but the line between what is permitted and what is infringing a patent is not yet fully clear.
PIC reports to Ministers on treatment of similar biologics
14 June, 2012 by AusBiotechThe Pharmaceuticals Industry Council (PIC), with members AusBiotech, Medicines Australia and the GMiA, has reported to the Federal Government on the preferred treatment of follow-on biologics for reimbursement.
ResMed launches sleep apnoea device in US
14 June, 2012 by Dylan Bushell-EmblingResMed (ASX:RMD) has brought Narval CC, an alternative treatment to PAP therapy for snoring and sleep apnoea, to the US market.
Opinion: The brutal truth about innovation in Australia
14 June, 2012 by Staff WritersDr Rowan Gilmore, CEO of the Australian Institute for Commercialisation, wonders whether Australian government and business are truly hungry enough to drive innovation in this country.
CSL gets orphan drug status for haemophilia-B treatment
13 June, 2012 by Dylan Bushell-EmblingCSL's (ASX:CSL) plasma protein unit, CSL Behring, has received US FDA orphan drug designation for a haemophilia-B treatment, rIX-FP.
NIH puts $4.5m into superbug killers
13 June, 2012 by Tim DeanThe Monash Institute of Phermaceutical Sciences has received a $4.48 million grant from the US National Institutes of Health to develop new antibiotics to combat multidrug-resistant bacteria.
Universal Biosensors to get $1.5m from Siemens
12 June, 2012 by Dylan Bushell-EmblingUniversal Biosensors (ASX:UBI) has achieved the first of six milestones under its coagulation testing collaboration with Siemens Healthcare Diagnostics.
ImpediMed wins “Life Changing Technology” award
12 June, 2012 by AusBiotechImpediMed Limited (ASX:IPD) has been recognised for making “the biggest difference on an individual while addressing the greatest medical need” for its bioelectrical impedance analysis (BIA) technology.
Pharmaxis debuts Bronchitol in EU
08 June, 2012 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) has officially launched its Bronchitol spray in the UK and Germany, and presented more trial data showing its efficacy.
Mesoblast to push development of dental pulp stem cells
08 June, 2012 by Dylan Bushell-EmblingMesoblast's (ASX:MSB) CEO has detailed plans to work with partner Teva to commercialise off-the-shelf adult dental pulp stem cells (DPSCs) for neurological conditions.
Prima BioMed’s incoming CEO to refocus company on CVac
08 June, 2012 by Tim DeanIncoming CEO and present COO of Prima BioMed, Matt Lehman, will refocus the company’s efforts on progressing CVac through clinical trials.
